Key facts
- About 600 jobs were cut from AstraZeneca's US respiratory and immunology commercial teams, per Bloomberg News.
- AstraZeneca said in late October it planned to save about $1.5 billion annually and reinvest in its pipeline.
- Some affected employees are expected to be reassigned within the company, Bloomberg News reported.
- AstraZeneca's immunology and respiratory portfolio was 16% of third-quarter revenue at $2.5 billion.
- AstraZeneca declined to comment on the report.
AstraZeneca has cut about 600 jobs from its respiratory and immunology commercial teams in the US as part of a three-year cost-savings initiative, Bloomberg News reported on November 13, 2026, citing people familiar with the matter. The UK-based drugmaker declined to comment on the report.
The cuts follow AstraZeneca's late-October announcement that it planned to save about $1.5 billion annually and reinvest in its drug pipeline. Some employees affected by the restructuring are expected to be reassigned within the company, Bloomberg News reported.
The reductions come as CEO Pascal Soriot seeks to reassure investors that AstraZeneca can meet its target of $80 billion in annual revenue by 2030, while drugmakers more broadly face growing scrutiny over the strength of their pipelines. AstraZeneca's immunology and respiratory portfolio accounted for 16% of its third-quarter revenue at $2.5 billion.